TB Diagnostics in Low-Resource Settings Remain Inadequate — Sputum Smear Misses 40-60% of Cases

Tuberculosis kills 1.3M people/year (2nd deadliest infectious disease after COVID). In low-resource settings where 95% of TB deaths occur, the primary diagnostic (sputum smear microscopy) misses 40-60% of cases, especially in HIV co-infected and pediatric patients.

Sputum smear microscopy requires 5,000-10,000 bacilli/mL for detection (sensitivity 50-60% overall, 20-30% in HIV+). Xpert MTB/RIF (GeneXpert) is more sensitive (~85%) and detects rifampicin resistance, but requires $17,000 instrument + $10/test + stable electricity. Culture (gold standard) takes 2-8 weeks and requires BSL-3 facilities. Lateral flow urine LAM tests (Alere Determine) are rapid but only sensitive in severely immunocompromised patients. WHO endorsed Truenat and portable NAAT platforms but coverage remains limited.

Why It Matters

10.6M new TB cases/year globally, 1.3M deaths. TB is the leading killer of people with HIV. MDR-TB treatment costs $2,000-200,000 per patient and takes 9-20 months. Early accurate diagnosis could reduce transmission by 50%+ and improve treatment success rates from 86% to >95%.

Startup Approach

Develop a truly point-of-care TB test: battery-operated, requires no sputum processing, results in <30 minutes, costs <$3/test. Potential approaches include CRISPR-based detection (SHERLOCK/DETECTR adapted for Mtb), isothermal amplification on paper-based lateral flow, or volatile organic compound (VOC) breath test using low-cost sensors.

NIH Funding

NIAID funds TB diagnostics research. Fogarty International Center supports global health diagnostics. BARDA funds pandemic preparedness diagnostics.

Who's Working On It

Cepheid (GeneXpert, Xpert MTB/RIF), Molbio Diagnostics (Truenat), FIND (diagnostics accelerator), Bill & Melinda Gates Foundation (TB diagnostics), Global Drug Facility